NCT05553080

Brief Summary

Colorectal carcinoma is a major health problem. As a malignant tumor, the malignant potential of colorectal carcinoma is based mainly on its ability to metastasis to different sites. Fascin-1 is an actin binding protein which is involved in reconstruction of intracellular actin network, the latter enforces the neoplastic cell to invade surrounding structures.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jan 2022

Shorter than P25 for all trials

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2022

Completed
9 months until next milestone

First Submitted

Initial submission to the registry

September 21, 2022

Completed
2 days until next milestone

First Posted

Study publicly available on registry

September 23, 2022

Completed
7 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 30, 2022

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2022

Completed
Last Updated

April 12, 2023

Status Verified

October 1, 2022

Enrollment Period

9 months

First QC Date

September 21, 2022

Last Update Submit

April 11, 2023

Conditions

Cancer of Colon

Keywords

Cancer ColonFascin-1Actin assembly

Outcome Measures

Primary Outcomes (1)

  • Evaluation of immunohistochemical staining of colorectal carcinoma by Fascin-1

    correlation of different levels of Fascin-1 expression to patients' ages, sexes, tumor stage, nodal metastasis, vascular and perineural invasion.

    September , 2022

Interventions

ImmunohistochemistryGENETIC

immunohistochemical staining of colorectal carcinoma specimens by anti human fascin antibody.

Eligibility Criteria

Age30 Years - 90 Years
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients had colorectal carcinoma who underwent radical colectomy operations in Sohag University Hospital, Sohag, Egypt.

You may qualify if:

  • All cases of colorectal carcinoma.

You may not qualify if:

  • cases diagnosed on basis of lower endoscopic biopsies or local resections without radical colectomy.
  • Patients with preopoerative history of chemo or radiotherapy.
  • Patients with poor clinical data.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Maisa Hashem Mohammed

Sohag, 82524, Egypt

Location

Sohag faculty of medicine

Sohag, 82524, Egypt

Location

MeSH Terms

Conditions

Colonic Neoplasms

Interventions

Immunohistochemistry

Condition Hierarchy (Ancestors)

Colorectal NeoplasmsIntestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesColonic DiseasesIntestinal Diseases

Intervention Hierarchy (Ancestors)

HistocytochemistryCytological TechniquesClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisHistological TechniquesInvestigative TechniquesImmunologic Techniques

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Lecturer of Pathology

Study Record Dates

First Submitted

September 21, 2022

First Posted

September 23, 2022

Study Start

January 1, 2022

Primary Completion

September 30, 2022

Study Completion

December 1, 2022

Last Updated

April 12, 2023

Record last verified: 2022-10

Locations

EG(2)